Top Watches for Wednesday.

NEOT, PLX, DEST, SRAX

---

NEOT - Neothetics merger with Evofem biosciences.  After its impressive run yesterday, It's trending sideways in premarket.  I still think this stock is overextended but I will wait for price action. If it does continue to uptrend I'll be watching for the price to break above the $2 resistance level. 

SRAX - Engaged financial advisors to explore strategic alternatives for business. Has a pattern of spiking for one day and fading for the next 3-5 days before the next spike. Looks like it might be good odds for a short play. 

DEST - Rumor about 50% more sales than expected for Q3, as well as $10-$11 Million in additional savings. Also, this is a BAD BAD BAD sushi chart. I would never hold this overnight or play premarket. Support looks to be @ $2.40. so I will be watching for price to hold above this level before trading during market hour.

PLX - Entered into a Partnership with Chiesi (a 1.236 billion EUR company). Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein. Protalix to receive $25 Million upfront, an additional up to $25 Million in development costs and an additional up to $320 Million in potential regulatory and commercial milestone payments. I'll be looking for this stock to hold  $0.65 support if not I'm not interested. With the stock already being up 0.89 I won't be looking to trade it unless it can break above the $1 resistance level. Not interested in a 10cent gain.

---

Just Watching

BNTC - announce that a new patent relating to the Company's hepatitis B program has been issued in the United States.  Titled "HBV Treatment" and issued as U.S. Patent Number 9,790,502, it encompasses Benitec's RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B (HBV) infection. 

OPTT - No news for being up after hours on Tuesday afternoon. 

 

CLD - Multi Month breakout with no other real catalyst.

IDXG - announced today the presentation of new data based on actual clinical results for 3,471 patients tested with the Company’s ThyGenX® /ThyraMIR® molecular tests for indeterminate thyroid nodules at the annual meeting of The American Thyroid Association (ATA). ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

TRXC, HMNY